URGN
UroGen Pharma Ltd
36.80$
-0.4%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.2% | -17.2% | -25.1% | +1.1% | +15.0% | +62.4% | +19.9% | +7.2% | +6.3% | -4.0% | +2.5% | – | |
| – | +17.4% | +5.6% | +29.2% | -2.0% | -5.3% | -7.1% | -10.9% | +10.8% | +3.4% | +47.8% | +15.2% | – | |
| – | – | -160.9% | – | -455.5% | – | -116.7% | – | -357.7% | – | – | – | – | |
| – | -46.5% | +0.0% | +56.9% | +14.3% | +19.8% | -61.7% | +220.5% | -38.3% | -80.5% | +217.6% | +11.1% | – | |
| – | -2,928.9% | – | -11.2% | -989.7% | – | -142.8% | – | +10.5% | -11.7% | -174.6% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | -100.6% | – | |
| – | -100.0% | +136,542.5% | +83.5% | -60.5% | -99.8% | -52.1% | +770.6% | +2,694.6% | +278.6% | +108.2% | -99.2% | – | |
| – | -124.5% | – | +143.0% | -207.1% | – | -244.4% | – | – | – | -103.9% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.